

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arix Bioscience plc</u> <hr/> (Last) (First) (Middle) 20 BERKELEY SQUARE <hr/> (Street) MAYFAIR, X0 W1J 6EQ LONDON <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/07/2019	3. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc. [HARP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Convertible Preferred Stock	(I)	(I)	Common stock	1,720,698	0.00	I	See footnote ⁽²⁾
Series C Convertible Preferred Stock	(I)	(I)	Common stock	742,850	0.00	I	See footnote ⁽²⁾

1. Name and Address of Reporting Person* <u>Arix Bioscience plc</u> <hr/> (Last) (First) (Middle) 20 BERKELEY SQUARE <hr/> (Street) MAYFAIR, X0 W1J 6EQ LONDON <hr/> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Arix Bioscience Holdings Ltd</u> <hr/> (Last) (First) (Middle) 20 BERKELEY SQUARE <hr/> (Street) MAYFAIR, X0 W1J 6EQ LONDON <hr/> (City) (State) (Zip)

Explanation of Responses:

1. The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock will each automatically convert into the number of shares of common stock of Harpoon Therapeutics, Inc. (the "Issuer") on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

2. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Remarks:

Arix Bioscience Plc, by: /s/
James Rawlingson, Chief
Financial Officer 02/07/2019

Arix Bioscience Holdings
Limited, by: /s/ James
Rawlingson, Authorized
Officer 02/07/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.